Dated: May 17, 2012.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2012-12675 Filed 5-23-12; 8:45 am]

BILLING CODE 4163-18-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Administration for Children and Families

# Proposed Information Collection Activity; Comment Request

#### **Proposed Projects**

*Title:* FPLS Child Support Services Portal Registration (FCSSP).

OMB No.: 0970-0370.

Description: The purpose of the Federal Child Support Services Portal Registration is to collect information from an authorized individual registering to use the FPLS Child Support Services Portal. This information collection is necessary to authenticate the individual's identity and comply with the statutory requirement that OCSE establish and implement safeguards to restrict access to confidential information in the FPLS to authorized persons. 42 U.S.C. 653(m)(2).

After identity is authenticated, secure accounts will be created for authorized users to view data for their respective applications.

Respondents: Employers, Financial Institutions, Insurers, State Agencies, Local Access and Visitation Providers.

### ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Registration Screens	588	1	0.10	58.8

Estimated Total Annual Burden Hours: 58.8.

In compliance with the requirements of Section 506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L'Enfant Promenade SW., Washington, DC 20447. Attn: ACF Reports Clearance Officer. Email address:

infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to

comments and suggestions submitted within 60 days of this publication.

#### Robert Sargis,

Reports Clearance Officer. [FR Doc. 2012–12601 Filed 5–23–12; 8:45 am] BILLING CODE 4184–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Food and Drug Administration**

[Docket No. FDA-2012-N-1029]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Licensing Provisions; Section 351(k) Biosimilar Applications

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by June 25, 2012.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202395–7285, or emailed to oira\_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–New and title "General Licensing Provisions; Section 351(k) Biosimilar Applications". Also include the FDA docket number found in brackets in the heading of this document.

## FOR FURTHER INFORMATION CONTACT:

Juanmanuel Vilela, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, 301–796–7651,

juanmanuel.vilela@fda.hhs.gov.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

# General Licensing Provisions; Section 351(k) Biosimilar Applications—(OMB Control Number 0910—New)

On March 23, 2010, the President signed into law the Patient Protection and Affordable Care Act (Affordable Care Act) (Pub. L. 111–148). The Affordable Care Act contains a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) which amends the Public Health Service Act (PHS Act) and establishes an abbreviated licensure pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product. (See sections 7001 through 7003 of the Affordable Care Act.)

Section 351(k) of the PHS Act (42 U.S.C. 262(k)), added by the BPCI Act,